Experts discuss the evolving role of radiopharmaceuticals in advanced prostate cancer

Dr. Pedro Barata and Dr. Johann de Bono wrapped up a series on metastatic castration-resistant prostate cancer by looking ahead to how radiopharmaceutical treatments may shape care.

They highlighted that ongoing research is expanding the range of radioactive agents that can target tumor cells, potentially improving outcomes for patients whose disease no longer responds to hormone therapy.

The authors also noted that future work will need to address optimal patient selection, combination strategies with other therapies, and management of safety and toxicity.

Overall, they expressed optimism that these advances could lead to more personalized and effective treatment pathways for men with advanced prostate cancer.